|
    
|
Leukemia Research Studying AML Studying B-CLL
Clinical outcome of b-cell type chronic lymphocytic leukemia varies from patient to patient. Some experience a rapid progression of the cancer with a fatal outcome, while others develop a more stable disease with normal life expectancies. The ability to recognize the different forms of this disease quickly is important for those who need the most aggressive treatment. While a valid prognosis can be made, this is labor intensive process require a team of professionals of varied clinical specialties.
|
|
This site was created for informational purposes and is part
of the Please visit our other sites at: Site creator: Fred Ayers |
The
DNA Microarray:
In
2005, Schoers et al. studied a group of 252 patients with B-CLL. Patients
were grouped into three categories based on their expression (or non-expression)
of ZAP-70 and CD38 proteins, which they showed were related to a positive or
negative prognosis. Their gene expression profile was then characterized using
an Affymetrix produced oligonucleotide microarray which probed for approximately
5600 genes and compared it against a subset of 35 patients whose gene expression
profile was already known from another published study. Through supervised
analysis, they were able to identify 37 genes that exhibited a distinct profile
between the three categories. This study supports the assertion made
by Schwaenen et. el in a 2004 paper that automated array-based genetic
profiling could be performed in a clinical setting.